The IL-6/Janus kinase (JAK)/STAT3 pathway is aberrantly hyperactivated in many types of cancer, including prostate cancer, and such hyperactivation is generally associated with a poor prognosis [241,242,243]. This evidence concerns the gene STAT3 and prostate carcinoma.